January 26, 2006
Boston Scientific Corporation and Guidant Corporation announce merger agreement, whereby Boston Scientific will acquire all of the outstanding shares of Guidant for a combination of cash and stock worth $80 per Guidant share, or approximately $27 billion.
As reported widely in the press, it was announced on January 25 that Boston Scientific Corporation and Guidant Corporation have entered into a merger agreement, whereby Boston Scientific will acquire all of the outstanding shares of Guidant for a combination of cash and stock worth $80 per Guidant share, or approximately $27 billion. Willkie represented Merrill Lynch & Co. and Bear Stearns & Co., which served with Banc of America Securities LLP as financial advisors to Boston Scientific. Prior to forging this agreement with Boston Scientific, Guidant terminated its previous merger agreement with Johnson & Johnson. The merger will create one of the world’s leading medical device companies with $9 billion in total revenue in 2006. Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices used in a broad range of interventional medical specialties. Willkie partner Steven Seidman and associates Laura Delanoy, Matthew Lux and David Mrazik handled the transaction.
